• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

How was the meeting?

Quote




I'm sure they're all busy flying home on their personal time after another "challenger certification" and are mandated to be in the field in the morning. They were probably brainwashed to believe they are lucky to work there.
 




Big Picture: Neuro needs to kick it in high gear. Belviq all intents and purposes dead.
Bigger Picture: Challenger is our almighty savior. We will be Phoenix rising from the ashes with Challenger and NICM.
 




anonymous said:
Big Picture: Neuro needs to kick it in high gear. Belviq all intents and purposes dead.
Bigger Picture: Challenger is our almighty savior. We will be Phoenix rising from the ashes with Challenger and NICM.
Click to expand...
Obviously, you were smoking crack when you wrote this. For the quadrillionth time but maybe the first time on CP: Fycompa has limited potential. Why? Because of the boxed warning AND the inclusion of homicidal ideation in that warning AND the FACT that a decent portion of doctors who have written Fycompa have actually seen some of the behavioral effects in their patients so they shy away from it AND because there is a number of other anticonvulsants that can treat POS, PGTC, and SGTC AND many of those are generic AND doctors have a shit ton of good experience using those alternatives AND have a much higher comfort level with those alternatives AND that's not gonna change. Got it? So you have a lot of Neuros who will never write Fycompa, others who wrote it but won't write for it again, still others who will give you one patient a year because you bring them lunch and pester them, and then others who will write for it but only after they've tried 5 or 6 others AEDs. The bottom line is this: is there a place for Fycompa and do some patients benefit from it? Absolutely. Will it continue to grow? Sure. BUT, it will NEVER reach the status in Rxs or sales$ that past management thought it would or that current management thinks it can. Nothing is going to change that. Not Challenger, not new management, not laying off old talent and bringing new talent- many of whom don't know Jack Shit about the epilepsy market, etc.... Anybody who's been in Pharma long enough and has seen or participated in many drug launches knows that by the end of year three, you know what the market potential of your drug is for a given indication. I have it on good authority that Fycompa sales in the US in fiscal 2016 (year 3) are gonna be around $60 million. Vimpat is around 375-400 million. So I say to current NBG management, "dream on". You fuckers have no clue, are delusional, or you know what you're doing by selling upper management the BS so you can keep collecting your overpaid salaries for as long as they keep buying the shit you're selling. Hey Ivan put the Clearisil down and listen, you want to save a shit ton of money and achieve the same or better sales results? Carve the fucking country up into 35-40 territories that matter. Put in those territories the very best you have (easy to gauge by looking at first year launch and second year results/rankings) and let them keep the doctors they've been calling on and developing solid relationships with, give them total dirt, and stop establishing quotas that your own sales forecasting folks think are unreasonable. Got it? You're welcome.
 




[QUOTE="let them keep the doctors they've been calling on and developing solid relationships with, give them total dirt, and stop establishing quotas that your own sales forecasting folks think are unreasonable. Got it? You're welcome.[/QUOTE] Could not have said it better myself!
 












anonymous said:
[QUOTE="let them keep the doctors they've been calling on and developing solid relationships with, give them total dirt, and stop establishing quotas that your own sales forecasting folks think are unreasonable. Got it? You're welcome.
Click to expand...
Could not have said it better myself![/QUOTE]

So the ridiculous goals are on the neurology side too. Thought was just oncology. Becca got us one quarter of reasonable goals. Expect them to skyrocket again. Based on forecast mine was cut in half. Tells you how inflated it was.
 








The meeting was a joke. Standing ovations,mic drops,f bombs. Very unprofessional leadership. Oh and now ear buds excite Doctors to quiet the noise. The food was bad,encouragement bad,Aric's fake tears bad. Most people kissed butt and stroked egos just to get by until they find a better job.
 




















Top Bottom
Back
Quote